On June 9, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference (Press release, Revolution Medicines, JUN 9, 2022, View Source [SID1234615824]). Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

Conference Date: June 13 – 16, 2022
Fireside Chat Details: 1:20 p.m. Pacific on Wednesday, June 15, 2022
A live webcast of the fireside chat can be accessed at: View Source An archived replay of the webcast will be available on the investors section of the company’s website for at least 14 days following the event.